These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

192 related articles for article (PubMed ID: 26840480)

  • 1. Simvastatin Efficiently Lowers Small LDL-IgG Immune Complex Levels: A Therapeutic Quality beyond the Lipid-Lowering Effect.
    Hörl G; Froehlich H; Ferstl U; Ledinski G; Binder J; Cvirn G; Stojakovic T; Trauner M; Koidl C; Tafeit E; Amrein K; Scharnagl H; Jürgens G; Hallström S
    PLoS One; 2016; 11(2):e0148210. PubMed ID: 26840480
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effects of ezetimibe/simvastatin on lipoprotein subfractions in patients with primary hypercholesterolemia: an exploratory analysis of archived samples using two commercially available techniques.
    Ose L; Reyes R; Johnson-Levonas AO; Sapre A; Tribble DL; Musliner T
    Clin Ther; 2007 Nov; 29(11):2419-32. PubMed ID: 18158082
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pitavastatin: novel effects on lipid parameters.
    Chapman MJ
    Atheroscler Suppl; 2011 Nov; 12(3):277-84. PubMed ID: 22152282
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Relationship between plasma phospholipase A2 concentrations and lipoprotein subfractions in patients with stable coronary artery disease.
    Xu RX; Zhang Y; Li XL; Li S; Guo YL; Dong Q; Liu G; Li JJ
    Clin Chim Acta; 2015 Jun; 446():195-200. PubMed ID: 25934512
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of simvastatin in familial hypercholesterolemia on the affinity of electronegative low-density lipoprotein subfractions to the low-density lipoprotein receptor.
    Benítez S; Ordóñez-Llanos J; Franco M; Marín C; Paz E; López-Miranda J; Otal C; Pérez-Jiménez F; Sánchez-Quesada JL
    Am J Cardiol; 2004 Feb; 93(4):414-20. PubMed ID: 14969613
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Concordance between plasma apolipoprotein B levels and cholesterol indices among patients receiving statins and nonstatin treatment: Post-hoc analyses from the U.K. InPractice study.
    Idris I; Tate H; Ahmad A; McCormack T
    J Clin Lipidol; 2011; 5(4):316-23. PubMed ID: 21784378
    [TBL] [Abstract][Full Text] [Related]  

  • 7. High-dose atorvastatin reduces total plasma levels of oxidized phospholipids and immune complexes present on apolipoprotein B-100 in patients with acute coronary syndromes in the MIRACL trial.
    Tsimikas S; Witztum JL; Miller ER; Sasiela WJ; Szarek M; Olsson AG; Schwartz GG;
    Circulation; 2004 Sep; 110(11):1406-12. PubMed ID: 15353498
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Relationship between biomarkers of oxidized low-density lipoprotein, statin therapy, quantitative coronary angiography, and atheroma: volume observations from the REVERSAL (Reversal of Atherosclerosis with Aggressive Lipid Lowering) study.
    Choi SH; Chae A; Miller E; Messig M; Ntanios F; DeMaria AN; Nissen SE; Witztum JL; Tsimikas S
    J Am Coll Cardiol; 2008 Jul; 52(1):24-32. PubMed ID: 18582631
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Oxidized low-density lipoprotein in children with familial hypercholesterolemia and unaffected siblings: effect of pravastatin.
    Rodenburg J; Vissers MN; Wiegman A; Miller ER; Ridker PM; Witztum JL; Kastelein JJ; Tsimikas S
    J Am Coll Cardiol; 2006 May; 47(9):1803-10. PubMed ID: 16682304
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The efficacy of statin monotherapy uptitration versus switching to ezetimibe/simvastatin: results of the EASEGO study.
    Roeters van Lennep HW; Liem AH; Dunselman PH; Dallinga-Thie GM; Zwinderman AH; Jukema JW
    Curr Med Res Opin; 2008 Mar; 24(3):685-94. PubMed ID: 18226326
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Detection of IgG-bound lipoprotein(a) immune complexes in patients with coronary heart disease.
    Wang J; Qiang H; Zhang C; Liu X; Chen D; Wang S
    Clin Chim Acta; 2003 Jan; 327(1-2):115-22. PubMed ID: 12482626
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effects of increasing doses of simvastatin on fasting lipoprotein subfractions, and the effect of high-dose simvastatin on postprandial chylomicron remnant clearance in normotriglyceridemic patients with premature coronary sclerosis.
    van Wijk JP; Buirma R; van Tol A; Halkes CJ; De Jaegere PP; Plokker HW; van der Helm YJ; Castro Cabezas M
    Atherosclerosis; 2005 Jan; 178(1):147-55. PubMed ID: 15585212
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effects of ezetimibe, simvastatin and ezetimibe/simvastatin on correlations between apolipoprotein B, LDL cholesterol and non-HDL cholesterol in patients with primary hypercholesterolemia.
    Farnier M; Guyton JR; Jensen E; Polis AB; Johnson-Levonas AO; Brudi P
    Atherosclerosis; 2013 Aug; 229(2):415-22. PubMed ID: 23880197
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Low-density lipoprotein cholesterol/apolipoprotein B ratio may be a useful index that differs in statin-treated patients with and without coronary artery disease: a case control study.
    Tani S; Saito Y; Anazawa T; Kawamata H; Furuya S; Takahashi H; Iida K; Matsumoto M; Washio T; Kumabe N; Nagao K; Hirayama A
    Int Heart J; 2011; 52(6):343-7. PubMed ID: 22188706
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Genetic diagnosis of familial hypercholesterolemia in a South European outbreed population: influence of low-density lipoprotein (LDL) receptor gene mutations on treatment response to simvastatin in total, LDL, and high-density lipoprotein cholesterol.
    Chaves FJ; Real JT; García-García AB; Civera M; Armengod ME; Ascaso JF; Carmena R
    J Clin Endocrinol Metab; 2001 Oct; 86(10):4926-32. PubMed ID: 11600564
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effects of pioglitazone and/or simvastatin on low density lipoprotein subfractions in non-diabetic patients with high cardiovascular risk: A sub-analysis from the PIOSTAT study.
    Leonhardt W; Pfützner A; Müller J; Pietzsch J; Forst T; Karagiannis E; Lübben G; Hanefeld M
    Atherosclerosis; 2008 Nov; 201(1):155-62. PubMed ID: 18374336
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Relationship of oxidized phospholipids and biomarkers of oxidized low-density lipoprotein with cardiovascular risk factors, inflammatory biomarkers, and effect of statin therapy in patients with acute coronary syndromes: Results from the MIRACL (Myocardial Ischemia Reduction With Aggressive Cholesterol Lowering) trial.
    Fraley AE; Schwartz GG; Olsson AG; Kinlay S; Szarek M; Rifai N; Libby P; Ganz P; Witztum JL; Tsimikas S;
    J Am Coll Cardiol; 2009 Jun; 53(23):2186-96. PubMed ID: 19497447
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Autoantibodies to malondialdehyde-modified low-density lipoprotein in patients with angiographically confirmed coronary artery disease.
    McDowell A; Young IS; Wisdom GB
    J Pharm Pharmacol; 2002 Dec; 54(12):1651-7. PubMed ID: 12542895
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Statins do not decrease small, dense low-density lipoprotein.
    Choi CU; Seo HS; Lee EM; Shin SY; Choi UJ; Na JO; Lim HE; Kim JW; Kim EJ; Rha SW; Park CG; Oh DJ
    Tex Heart Inst J; 2010; 37(4):421-8. PubMed ID: 20844614
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Guideline-oriented ambulatory lipid-lowering therapy of patients at high risk for cardiovascular events by cardiologists in clinical practice: the 2L cardio registry.
    Gitt AK; Juenger C; Jannowitz C; Karmann B; Senges J; Bestehorn K
    Eur J Cardiovasc Prev Rehabil; 2009 Aug; 16(4):438-44. PubMed ID: 19369876
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.